Loading
Safusidenib is an experimental small molecule inhibitor from Nuvation Bio in phase 3 trials for glioma & glioblastoma, aimed at IDH1 / IDH2.
Safusidenib (AB-218) is a small molecule inhibitor developed by Nuvation Bio. Its target is IDH1 / IDH2 (the sponsor names IDH1-mutant glioma). The sponsor states: novel, oral, potent, brain-penetrant, targeted inhibitor of mutant IDH1. ClinicalTrials.gov describes the intervention as: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05303519 (SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)), in glioma & glioblastoma. The largest, NCT05303519, plans to enrol 365 participants with primary completion expected 2028-12-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
novel, oral, potent, brain-penetrant, targeted inhibitor of mutant IDH1. Connects to IDH1 / IDH2.
1.Safusidenib slips into a pocket on IDH1 / IDH2.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Safusidenib" OR ABSTRACT:"Safusidenib" OR TITLE:"AB-218" OR ABSTRACT:"AB-218" OR TITLE:"DS-1001b" OR ABSTRACT:"DS-1001b") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Safusidenib, not a curated reading list.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Glioma & glioblastoma and the tag pipeline.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Glioma & glioblastoma and the tag pipeline.
Shares Nuvation Bio and the tag pipeline.
Shares Nuvation Bio and the tag pipeline.
Shares IDH1 / IDH2 and the tag pipeline.
Shares IDH1 / IDH2 and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.